ClinicalTrials.gg
WithdrawnNCT04216797Updated Apr 19, 2023

Rectal Versus Oral Diazepam Administration in the Treatment of Levator Ani Syndrome

A Phase 4 interventional study of Diazepam Tablets in Levator Ani Syndrome, sponsored by Swedish Medical Center. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-04-19.

Sponsored by Swedish Medical Center · Phase 4, Interventional, and Treatment

How we know

Why this study was withdrawn
Enrollment was initially suspended due to COVID pandemic. As the number of cases subsided, enrollment was reopened but never regained momentum. PI has left the site.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This research involves collecting data about levator ani syndrome (LAS) associated rectal pain and a comparison of diazepam treatment administration routes. The goal of this research is to see if an alternative route of diazepam administration provides sufficient control of LAS discomfort and low sleep quality while minimizing systemic effects of diazepam (drowsiness).

Read the detailed description

Levator ani syndrome (LAS) is described as a dull, aching pain of a patient's pelvic floor musculature. There is no known cause for the syndrome, yet pelvic floor muscle spasm and increased anal resting pressures have been hypothesized to result in the syndrome. LAS is commonly seen in patients with constipation, specifically outlet dysfunction constipation. Treatment for the syndrome involves a combination of bowel management, medications, and pelvic floor physical therapy (PT). Pelvic floor PT uses a variety of methods to help patients with LAS, including biofeedback and massage. The literature and the investigators experience shows that these pelvic floor PT approaches do not resolve all LAS symptoms.

Diazepam (Valium®) is used to treat levator ani syndrome in conjunction with other treatments to help relax the pelvic floor muscle group (levator ani). Diazepam has U.S. Food and Drug Administration (FDA) approval for use as a muscle relaxant. Investigators at Swedish Colon \& Rectal Clinic are using diazepam intervention as a means for patients to gain relief from pain.

The work proposed aims to provide the first prospective, randomized, comparative study of the efficacy between administering diazepam rectally and administering the medication orally after pelvic floor PT treatment. Currently, other ways of administering diazepam have not been studied in the setting of the LAS condition. The Investigators performed a retrospective chart review last year and found some promising results for the efficacy of rectal and oral routes of diazepam for LAS. The Investigators want to determine if the route of administering diazepam as an adjunct to pelvic floor PT influences rectal pain relief for LAS patients.

Primary Objective: Compare the pain scores of participants with LAS after administering diazepam rectally or orally following six weeks of physical therapy.

Secondary Objectives:

  1. Measure and compare the drowsiness levels of participants using rectal diazepam or oral diazepam. 2. Measure and compare the sleep quality of participants using rectal diazepam or oral diazepam.

All participants with the LAS diagnosis will initially receive 6 weeks of pelvic floor PT. After these six weeks, participants without effective pain relief will be randomized to one of two arms: rectal or oral diazepam administration. Participants will be dispensed 30 10 mg diazepam tablets to take daily (oral or rectal) for 4 weeks. Participants will be asked to complete 3 electronic questionnaires (VAS pain scale, Likert drowsiness scale, and Pittsburg Sleep Quality Index) each week while on the 10 week trial. Investigators plan to enroll 100 participants over approximately 5 years.

02

Conditions studied

  • Levator Ani Syndrome
03

In context

Lead sponsor

Swedish Medical Center is the lead sponsor of 40 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Patients with a diagnosis of LAS according to the Rome IV criteria with:

    1. Chronic or recurrent rectal pain or aching
    2. Episodes lasting 30 minutes or longer
    3. Tenderness during traction on the puborectalis
    4. Exclusion of other causes of rectal pain
  2. Patients who agree to undergo pelvic floor PT for six weeks prior to starting the medication treatment.
  3. Women ≥ 18 years of age. Women of must undergo urine pregnancy testing prior to using the treatment medication.
  4. Men ≥ 18 years of age.

Exclusion Criteria:

  1. Participants who have had pelvic floor surgery or with recent conditions in which rectal suppositories are .
  2. Non-English speaking participants.
  3. Women who are pregnant or breastfeeding.
  4. Participants who are cognitively impaired, illiterate, or have a condition in which they are unable to consent for themselves.
  5. Prisoners.
  6. Participants allergic to benzodiazepines or have a sensitivity/intolerance to benzodiazepines.
  7. Participants to which benzodiazepines are contraindicated or are on medications that interact with benzodiazepines.
  8. Participants with current or history of (DSM-V) substance use disorder or Participants with a history of evidence of severe illness or any other conditions that would affect absorption or make the patient unsuitable for the study in the opinion of the investigator.
  9. Participants already receiving medications in the benzodiazepine class within 2 weeks of screening visit for any reasons will be excluded based on increased risk for medication tolerance.
  10. Participants who have undergone pelvic floor PT within 2 weeks of screening visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Oral Administration

    10 mg diazepam tablets to be taken orally once daily for 4 weeks.

    Drug: Diazepam Tablets

  • Active comparator
    Rectal Administration

    10 mg diazepam tablets to be taken rectally once daily for 4 weeks.

    Drug: Diazepam Tablets

Interventions

  • DrugDiazepamStudies of DiazepamDiazepam pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will be randomly assigned to either an oral or rectal administration of once daily 10 mg diazepam tablets for four weeks.

06

What researchers measure

Primary outcomes

  1. Effectiveness of rectal administration versus oral administration in LAS pain management: Visual Analog Scale (VAS)

    Participants will complete weekly electronic Visual Analog Scale (VAS) for pain for 6 weeks while on Physical Therapy only, followed by 4 weeks while taking diazepam (orally or rectally). Participants will be asked to select a number on a scale of 1 to 10, where 1 equals no pain and 10 equals worst pain.

    Time frame: 10 weeks

Secondary outcomes

  1. Participant drowsiness while taking diazepam rectally versus orally

    Participants will complete weekly electronic Likert drowsiness scale for 6 weeks while on Physical Therapy only, followed by 4 weeks while taking diazepam (orally or rectally). Participants will be asked to select a number on a scale of 1 to 5, where 1 equals much less drowsiness than usual and 10 equals much more drowsiness than usual.

    Time frame: 10 weeks

  2. Participant sleep quality while taking diazepam rectally versus orally: Pittsburg Sleep Quality Index

    Participants will complete weekly electronic Pittsburg Sleep Quality Index for 6 weeks while on Physical Therapy only, followed by 4 weeks while taking diazepam (orally or rectally). The Pittsburg Sleep Quality Index measures overall sleep quality, evaluating seven categories of sleep: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. The seven individual categories are weighted on a 0-3 interval scale. The global Pittsburg Sleep Quality Index score is then calculated by adding the seven individual category scores, which then provides a total score ranging from 0 to 21, where lower scores represent a healthier sleep quality.

    Time frame: 10 weeks

  3. Study Medication Adherence

    Participants will be instructed to take diazepam (orally or rectally) daily for 4 weeks. Participants will bring in their pill bottles so that the study staff can manually count their pills to check for adherence.

    Time frame: 4 weeks

07

Study locations

1 site
  • Swedish Medical Center Colon Rectal Clinic
    Seattle, Washington 98104, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2020 to primary completion in Feb 2023, 37 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2019
First posted
Jan 3, 2020
StartActual
Jan 9, 2020
Primary completionActual
Feb 21, 2023
CompletionActual
Feb 21, 2023
Last update
Apr 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04216797
Lead sponsor
Swedish Medical Center
Responsible party
Sponsor
First posted
Jan 3, 2020
Start date
Jan 9, 2020
Primary completion
Feb 21, 2023
Completion
Feb 21, 2023
Last update
Apr 19, 2023

Study contacts

Cecilia A Lynn
principal investigator · Swedish Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diazepam

Start the discussion